We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+2.04%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$681M
AUM Growth
-$84.8M
Cap. Flow
-$23.2M
Cap. Flow %
-3.41%
Top 10 Hldgs %
54.41%
Holding
74
New
15
Increased
15
Reduced
15
Closed
16

Top Buys

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$38.2M
2
AUTL
Autolus Therapeutics
AUTL
+$15.6M
3
IMVT icon
Immunovant
IMVT
+$12.3M
4
IRON icon
Disc Medicine
IRON
+$12.1M
5
KROS icon
Keros Therapeutics
KROS
+$9.98M

Top Sells

Rank Stock Value
1
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$41.5M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$21.7M
3
TGTX icon
TG Therapeutics
TGTX
+$20.2M
4
CRDF icon
Cardiff Oncology
CRDF
+$13.2M
5
MYOV
Myovant Sciences Ltd.
MYOV
+$9.85M

Sector Composition

Rank Sector Weight
1 Healthcare 99.89%
2 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALPN
51
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.66M 0.24%
+156,500
New +$1.95M
WHWK
52
Whitehawk Therapeutics
WHWK
$278M
$1.29M 0.19%
+66,667
New +$1.53M
AYLA
53
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$1.18M 0.17%
+108,551
New +$1.55M
CFRX
54
DELISTED
ContraFect Corporation
CFRX
$1.17M 0.17%
3,050
-2,450
-45% -$1.06M
DNTH icon
55
Dianthus Therapeutics
DNTH
$6.24B
$1.05M 0.15%
5,525
+2,537
+85% +$427K
VIRX
56
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$958K 0.14%
+103,600
New +$1.08M
CYPH
57
Cypherpunk Technologies Inc
CYPH
$204M
$737K 0.11%
+38,810
New +$924K
BLRX
58
BioLineRX
BLRX
$12.1M
$47K 0.01%
417
– –
AMRN
59
Amarin Corp
AMRN
$297M
– –
-11,250
Closed -$1.1M
ATXS
60
DELISTED
Astria Therapeutics
ATXS
– –
-31,292
Closed -$402K
FULC icon
61
Fulcrum Therapeutics
FULC
$294M
– –
-88,300
Closed -$1.03M
KALV
62
DELISTED
KalVista Pharmaceuticals
KALV
– –
-470,203
Closed -$8.93M
MRUS
63
DELISTED
Merus
MRUS
– –
-353,000
Closed -$6.19M
PRAX icon
64
Praxis Precision Medicines
PRAX
$10.3B
– –
-4,228
Closed -$3.49M
RYTM icon
65
Rhythm Pharmaceuticals
RYTM
$7.75B
– –
-115,000
Closed -$3.42M
TGTX icon
66
TG Therapeutics
TGTX
$8.53B
– –
-387,500
Closed -$20.2M
INFI
67
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-3,171,800
Closed -$6.72M
CNCE
68
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-254,000
Closed -$3.21M
TCDA
69
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-959,000
Closed -$6.76M
AKUS
70
DELISTED
Akouos Inc
AKUS
– –
-45,459
Closed -$901K
CCXI
71
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-350,000
Closed -$21.7M
FPRX
72
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-381,900
Closed -$6.5M
FSDC
73
DELISTED
FS Development Corp. Class A Common Stock
FSDC
– –
-704,400
Closed -$7.75M
EIDX
74
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
– –
-315,550
Closed -$41.5M
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2021 Portfolio in Review

As of Q1 2021, Opaleye Management held 74 positions worth $681M, down 11% from $766M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Opaleye Management withdrew a net $23.2M in Q1 2021, closing 16 positions and reducing 15 holdings. Its most notable exit was Eidos Therapeutics, Inc. Common Stock, an estimated $41.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, Opaleye Management opened a new position in BridgeBio Pharma worth $36M.

  • Opaleye Management's largest Q1 2021 buy was BridgeBio Pharma: 583,767 shares worth $36M.
  • Opaleye Management added most to MacroGenics in Q1 2021, an estimated $7.18M increase.
  • Opaleye Management's biggest Q1 2021 reduction was Cardiff Oncology, cutting an estimated $13.2M.
  • Opaleye Management fully exited Eidos Therapeutics, Inc. Common Stock in Q1 2021, selling an estimated $41.5M.
  • Opaleye Management's ten largest holdings make up 54% of its $681M portfolio in Q1 2021.
  • Opaleye Management opened 15 new positions and closed 16 in Q1 2021.
  • Opaleye Management's portfolio value fell 11% quarter-over-quarter to $681M.

Based on Opaleye Management's 13F filing for Q1 2021, filed 18 May 2021.